Cargando…

IRS2 Amplification as a Predictive Biomarker in Response to Ceritinib in Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a fast-growing and malignant cancer that responds well to chemotherapy; however, the survival rate is less than 15% after 2 years of diagnosis. Therefore, novel therapeutic agents for treating SCLC patients need to be evaluated. This study aims to identify the therap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Mi-Sook, Jung, Kyungsoo, Song, Ji-Young, Sung, Min-Jung, Ahn, Sung-Bin, Lee, Boram, Oh, Doo-Yi, Choi, Yoon-La
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7029374/ https://www.ncbi.nlm.nih.gov/pubmed/32099898 http://dx.doi.org/10.1016/j.omto.2019.12.009

Ejemplares similares

Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification
por: Oh, Doo-Yi, et al.
Publicado: (2017)

Phenylethanolamine N-methyltransferase downregulation is associated with malignant pheochromocytoma/paraganglioma
por: Lee, Seung Eun, et al.
Publicado: (2016)

LYN expression predicts the response to dasatinib in a subpopulation of lung adenocarcinoma patients
por: Kim, Yu Jin, et al.
Publicado: (2016)

Cancer-Specific Sequences in the Diagnosis and Treatment of NUT Carcinoma
por: Lee, Mi-Sook, et al.
Publicado: (2023)

Ceritinib for ALK-Rearrangement–Positive Non–Small Cell Lung Cancer
por: Nix, Nancy M., et al.
Publicado: (2015)

Successful rechallenge with ceritinib after leukocytoclastic vasculitis during ceritinib treatment for non-small cell lung cancer harboring the EML4-ALK fusion protein
por: Okimoto, Tamio, et al.
Publicado: (2018)

Prevalence of Mutations in Discoidin Domain-Containing Receptor Tyrosine Kinase 2 (DDR2) in Squamous Cell Lung Cancers in Korean Patients
por: Lee, Mi-Sook, et al.
Publicado: (2017)

Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer
por: Burns, Mark W, et al.
Publicado: (2015)

Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma
por: Beck, Olaf, et al.
Publicado: (2020)

KRAS Mutation Detection in Non-small Cell Lung Cancer Using a Peptide Nucleic Acid-Mediated Polymerase Chain Reaction Clamping Method and Comparative Validation with Next-Generation Sequencing
por: Lee, Boram, et al.
Publicado: (2014)

TM4SF4 and LRRK2 Are Potential Therapeutic Targets in Lung and Breast Cancers through Outlier Analysis
por: Jung, Kyungsoo, et al.
Publicado: (2021)

Engrailed 1 overexpression as a potential prognostic marker in quintuple-negative breast cancer
por: Kim, Yu Jin, et al.
Publicado: (2018)

Amplification of distinct α-synuclein fibril conformers through protein misfolding cyclic amplification
por: Jung, Byung Chul, et al.
Publicado: (2017)

Acute Interstitial Lung Disease Induced by Rechallenge with Ceritinib
por: Hotta, Takamasa, et al.
Publicado: (2019)

Organizing pneumonia resembling disease progression in a non-small-cell lung cancer patient receiving ceritinib: A case report
por: Lim, Sun M., et al.
Publicado: (2018)

Novel targeted therapies for resistant ALK-rearranged non-small-cell lung cancer: ceritinib and beyond
por: Kanaan, Zeyad, et al.
Publicado: (2015)

New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib
por: Rothschild, Sacha I
Publicado: (2016)

Activity of ceritinib in crizotinib-resistant ROS1-rearranged non-small-cell lung cancer patients
por: Zhang, Huixian, et al.
Publicado: (2023)

Mechanisms of IR amplification in radical cation polarons
por: Kendrick, William J., et al.
Publicado: (2020)

Molecular changes in solitary fibrous tumor progression
por: Park, Hyung Kyu, et al.
Publicado: (2019)

An isothermal, label-free, and rapid one-step RNA amplification/detection assay for diagnosis of respiratory viral infections
por: Koo, Bonhan, et al.
Publicado: (2017)

HER2 as a novel therapeutic target for cervical cancer
por: Oh, Doo-Yi, et al.
Publicado: (2015)

P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer
por: Katayama, Ryohei, et al.
Publicado: (2015)

Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib
por: El-Osta, Hazem, et al.
Publicado: (2015)

Real-life experience of ceritinib in crizotinib-pretreated ALK(+) advanced non-small cell lung cancer patients
por: Cadranel, Jacques, et al.
Publicado: (2018)

Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy
por: Santarpia, Mariacarmela, et al.
Publicado: (2017)

Ceritinib‐associated hyperglycemia in the Japanese Adverse Drug Event Report Database
por: Fujita, Haruka, et al.
Publicado: (2019)

Crizotinib and ceritinib trigger immunogenic cell death via on-target effects
por: Petrazzuolo, Adriana, et al.
Publicado: (2021)

Ceritinib is a novel triple negative breast cancer therapeutic agent
por: Dong, Shengli, et al.
Publicado: (2022)

Comparison of METS-IR and HOMA-IR for predicting new-onset CKD in middle-aged and older adults
por: Yoon, Jihyun, et al.
Publicado: (2023)

Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases
por: Lee, Taebum, et al.
Publicado: (2016)

Novel Microsatellite Markers of Meretrix petechialis and Cross-species Amplification in Related Taxa (Bivalvia: Veneroida)
por: Kang, Jung-Ha, et al.
Publicado: (2012)

Frequent Amplification of CENPF, GMNN and CDK13 Genes in Hepatocellular Carcinomas
por: Kim, Hye-Eun, et al.
Publicado: (2012)

Cost-Effectiveness Analysis Of Ceritinib And Alectinib Versus Crizotinib In The Treatment Of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
por: Liu, Maobai, et al.
Publicado: (2019)

Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non–Small Cell Lung Cancer Cells
por: Dong, Xuyuan, et al.
Publicado: (2016)

Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer
por: Won, Brian, et al.
Publicado: (2016)

A case of ALK-rearranged non–small cell lung cancer that responded to ceritinib after development of resistance to alectinib
por: Makuuchi, Yosuke, et al.
Publicado: (2018)

A Phase 0 Trial of Ceritinib in Patients with Brain Metastases and Recurrent Glioblastoma
por: Mehta, Shwetal, et al.
Publicado: (2022)

The Clinical Significance of RAS, PIK3CA, and PTEN Mutations in Non-Small Cell Lung Cancer Using Cell-Free DNA
por: Chang, Won Jin, et al.
Publicado: (2020)

Aberrant CDK4 Amplification in Refractory Rhabdomyosarcoma as Identified by Genomic Profiling
por: Park, Silvia, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_7bm19f8knebu6stavj3afnp6ud